Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIN + Anti-PD1 in Refractory Advanced HCC
NCT07018518Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in hepatocellular carcinoma (HCC), sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of treatment-related Adverse Events at 12 months and Immune response assessed by CD8+ T cells. Started Jun 2025; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07018518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018518.